Stifel Financial
ABCL icon

Stifel Financial’s AbCellera Biologics ABCL Stock Holding History

Stifel Financial’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Buy
106,188
+21,644
+26% +$106K ﹤0.01% 2669
2026
Q1 		$295K Sell
84,544
-625
-0.7% -$2.25K ﹤0.01% 3195
2025
Q4 		$291K Sell
85,169
-17,609
-17% -$78.6K ﹤0.01% 3182
2025
Q3 		$517K Sell
102,778
-9,465
-8% -$41.7K ﹤0.01% 2791
2025
Q2 		$385K Buy
112,243
+44,579
+66% +$111K ﹤0.01% 2913
2025
Q1 		$151K Sell
67,664
-3,850
-5% -$11K ﹤0.01% 3234
2024
Q4 		$210K Sell
71,514
-3,300
-4% -$9.19K ﹤0.01% 3148
2024
Q3 		$195K Sell
74,814
-27,563
-27% -$76.4K ﹤0.01% 3148
2024
Q2 		$303K Sell
102,377
-6,900
-6% -$26.1K ﹤0.01% 2913
2024
Q1 		$495K Sell
109,277
-868
-0.8% -$4.43K ﹤0.01% 2614
2023
Q4 		$629K Buy
110,145
+45,522
+70% +$211K ﹤0.01% 2441
2023
Q3 		$297K Sell
64,623
-3,190
-5% -$19.4K ﹤0.01% 2795
2023
Q2 		$438K Sell
67,813
-4,809
-7% -$32.8K ﹤0.01% 2598
2023
Q1 		$548K Sell
72,622
-1,961
-3% -$17.8K ﹤0.01% 2465
2022
Q4 		$756K Buy
74,583
+326
+0.4% +$3.77K ﹤0.01% 2212
2022
Q3 		$734K Buy
74,257
+12,482
+20% +$137K ﹤0.01% 2178
2022
Q2 		$658K Buy
61,775
+22,450
+57% +$190K ﹤0.01% 2298
2022
Q1 		$383K Buy
39,325
+504
+1% +$4.77K ﹤0.01% 2728
2021
Q4 		$555K Sell
38,821
-31,699
-45% -$481K ﹤0.01% 2538
2021
Q3 		$1.41M Buy
70,520
+48,515
+220% +$858K ﹤0.01% 1822
2021
Q2 		$484K Buy
22,005
+14,736
+203% +$406K ﹤0.01% 2604
2021
Q1 		$247K Buy
+7,269
New +$290K ﹤0.01% 2903

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Stifel Financial's ABCL Position: Q2 2026 in Review

Stifel Financial increased its AbCellera Biologics (ABCL) stake by 26% in Q2 2026, buying an estimated $106K and bringing the position to 106,188 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #2669.

Stifel Financial first reported a position in ABCL in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.41M in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Stifel Financial held 106,188 shares of AbCellera Biologics worth $834K as of Q2 2026.
  • Stifel Financial bought 21,644 AbCellera Biologics shares in Q2 2026, an estimated $106K.
  • AbCellera Biologics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2669 holding.
  • Stifel Financial first reported a position in AbCellera Biologics in Q1 2021 and has held it in 22 quarters since.
  • Stifel Financial's AbCellera Biologics position peaked at $1.41M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.